. 2012 Nov 5;75(6):1525–1535. doi: 10.1111/bcp.12024

Table 3.

Covariate–parameter relationships identified for abacavir in previous population pharmacokinetic analyses

Study	Reference	Number of children	Age range (years)	Significant covariates in the model	Covariate–parameter relationship
PENTA 13	7	14	2.14–12.84	Bodyweight on CL and V	CL/F (l h⁻¹) = 37.2 × (BW/23.8)^0.553
PENTA 13	7	14	2.14–12.84	Bodyweight on CL and V	V/F (l) = 64.8 × (BW/23.8)^0.537
PENTA 15	12	18	0.42–2.81	Bodyweight on CL	CL/F (l h⁻¹) = 13.4 × (BW/12)^1.14
PENTA 13 + PENTA 15 + ARROW	Present study	69	0.42–12.84	Bodyweight on CL and V₁	CL/F (l h⁻¹) = 20.1 × (BW/17.6)^0.802
PENTA 13 + PENTA 15 + ARROW	Present study	69	0.42–12.84	Bodyweight on CL and V₁	V₁/F (l) = 13.0 × (BW/17.6)^0.810
Therapeutic drug monitoring data	11	105	0.0685–16	Bodyweight on CL and V	CL/F (l h⁻¹) = 24.3 × (BW/25)^1.0
Therapeutic drug monitoring data	11	105	0.0685–16	Bodyweight on CL and V	V/F (l) = 42.9 × (BW/25)^0.95